```
=> struc
ENTER NAME OF STRUCTURE TO BE RECALLED (NONE):l3
ENTER (DIS), GRA, NOD, BON OR ?:dis
```




```
VAR G1=H/A
ENTER (DIS), GRA, NOD, BON OR ?:end
L9   STRUCTURE CREATED

=> s l9 ful
FULL SEARCH INITIATED 10:39:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    58596 TO ITERATE

100.0% PROCESSED    58596 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.02

L10            0 SEA SSS FUL L9

=> d l5
L5 HAS NO ANSWERS
L5                STR
```




```
VAR G1=H/A
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC   5
NUMBER OF NODES IS  14

STEREO ATTRIBUTES: NONE
```

```
=> s l5 ful
FULL SEARCH INITIATED 10:40:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    58596 TO ITERATE

100.0% PROCESSED    58596 ITERATIONS                                 0 ANSWERS
SEARCH TIME: 00.00.02

L11           0 SEA SSS FUL L5
```

```
=> s wo2005067923/pn
L14          1 WO2005067923/PN
                (WO2005067923/PN)

=> d bib abs

L14  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2005:673109  CAPLUS
DN   143:172754
TI   Preparation of 7-indolecarboxamides as IKK2 kinase inhibitors for the
     treatment of such as inflammatory and tissue repair disorders
IN   Baldwin, Ian Robert; Bamborough, Paul; Christopher, John Andrew; Kerns,
     Jeffrey K.; Longstaff, Timothy; Miller, David Drysdale
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 169 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    -------------------    --------
PI   WO 2005067923        A1    20050728    WO 2005-GB85           20050113 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
     AU 2005205090        A1    20050728    AU 2005-205090         20050113
     CA 2552953           A1    20050728    CA 2005-2552953        20050113
     EP 1703905           A1    20060927    EP 2005-701855         20050113
     EP 1703905           B1    20081112
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS
     CN 1933830           A     20070321    CN 2005-80008362       20050113
     BR 2005006802        A     20070529    BR 2005-6802           20050113
     JP 2007517848        T     20070705    JP 2006-548393         20050113
     AT 413877            T     20081115    AT 2005-701855         20050113
     ES 2317184           T3    20090416    ES 2005-701855         20050113
     IN 2006DN03579       A     20070831    IN 2006-DN3579         20060621
     US 20080269200       A1    20081030    US 2006-597154         20060713
     MX 2006008080        A     20060920    MX 2006-8080           20060714
     NO 2006003676        A     20061013    NO 2006-3676           20060815
PRAI GB 2004-895          A     20040115
     WO 2005-GB85         W     20050113
OS   CASREACT 143:172754; MARPAT 143:172754
GI
```



I



II



III

AB Title compds. I [wherein R1, R2 = H, halo, alkylene, alkenylene, (hetero)aryl, etc., and salts, solvates, or physiol. functional derivs. thereof] were prepared as IKK2 kinase inhibitors. For instance, Pd-catalyzed coupling of Boc-protected bromide II (preparation given) with phenylboronic acid followed by deprotection with HCl gave 7-indolecarboxamide III. Most invented compds. were found to have activity >4.8 in the IKK2 assay, in which the degree of phosphorylation of GST-IκBα was measured as a ratio of specific 665 nm energy transfer signal to reference europium 620 nm signal. Therefore, I and their pharmaceutical compns. are useful in the treatment and prevention of disease states mediated by IKK2 mechanisms, including inflammatory and tissue repair disorders.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> analyze l14
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
L15 ANALYZE L14 1 RN : 390 TERMS

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.84	397.62

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.82	-0.82

FILE 'REGISTRY' ENTERED AT 10:44:02 ON 13 MAY 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAY 2009 HIGHEST RN 1145835-49-9
DICTIONARY FILE UPDATES: 12 MAY 2009 HIGHEST RN 1145835-49-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of

experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l15
L16   390 L15

=> d scan

L16 390 ANSWERS   REGISTRY COPYRIGHT 2009 ACS on STN
IN   1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(1H-pyrazol-
     4-yl)-
MF   C19 H23 N5 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l16 and indole
        567770 INDOLE
L17   228 L16 AND INDOLE

=> s l17 and carboximide
          4531 CARBOXIMIDE
L18   0 L17 AND CARBOXIMIDE

=> s l17 and carboxamide
       2911372 CARBOXAMIDE
L19   206 L17 AND CARBOXAMIDE

=> d scan

L19 206 ANSWERS   REGISTRY COPYRIGHT 2009 ACS on STN
IN   1H-Indole-7-carboxamide, 3-[1-[(2,4-difluorophenyl)sulfonyl]-4-
     piperidinyl]-5-phenyl-
MF   C26 H23 F2 N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> d 206

L19 ANSWER 206 OF 206 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860624-91-5 REGISTRY
ED Entered STN: 17 Aug 2005
CN 1H-Indole-7-carboxamide, 5-bromo- (CA INDEX NAME)
OTHER NAMES:
CN 5-Bromo-1H-indole-7-carboxamide
MF C9 H7 Br N2 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

5 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 205

L19 ANSWER 205 OF 206 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860624-94-8 REGISTRY
ED Entered STN: 17 Aug 2005
CN 1H-Indole-7-carboxamide, 3-iodo-5-phenyl- (CA INDEX NAME)
MF C15 H11 I N2 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 204

L19 ANSWER 204 OF 206 REGISTRY COPYRIGHT 2009 ACS on STN
RN 860625-06-5 REGISTRY
ED Entered STN: 17 Aug 2005
CN 1H-Indole-7-carboxamide, 5-phenyl- (CA INDEX NAME)
MF C15 H12 N2 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	24.12	421.74

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.82

FILE 'CAPLUS' ENTERED AT 10:46:28 ON 13 MAY 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 May 2009 VOL 150 ISS 20
FILE LAST UPDATED: 12 May 2009 (20090512/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate

=> s l15
THE ESTIMATED SEARCH COST FOR 'L15' FOR FILE 'CAPLUS' IS 1,747.20 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:end

=> s l19
L20   5 L19

=> d his

     (FILE 'HOME' ENTERED AT 10:35:27 ON 13 MAY 2009)

     FILE 'REGISTRY' ENTERED AT 10:35:36 ON 13 MAY 2009
L1   STRUC
L2   0 S L1
L3   STRUC
L4   0 S L3
L5   STRUC
L6   0 S L5
L7   STRUC
L8   0 S L7
L9   STRUC
L10   0 S L9 FUL
L11   0 S L5 FUL
L12   STRUC
L13   0 S L12

     FILE 'CAPLUS' ENTERED AT 10:42:56 ON 13 MAY 2009
L14   1 S WO2005067923/PN
L15   ANALYZE L14 1 RN :   390 TERMS

     FILE 'REGISTRY' ENTERED AT 10:44:02 ON 13 MAY 2009
L16   390 S L15
L17   228 S L16 AND INDOLE
L18   0 S L17 AND CARBOXIMIDE
L19   206 S L17 AND CARBOXAMIDE

     FILE 'CAPLUS' ENTERED AT 10:46:28 ON 13 MAY 2009

```
L20           5 S L19

=> s l20 not l14
L21           4 L20 NOT L14

=> d bib hitstr 1

L21  ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2008:1180115  CAPLUS
DN   149:425786
TI   Preparation of indolecarboxamide derivatives for use as IKK2 inhibitors
IN   Boehm, Jeffrey Charles; Busch-Petersen, Jakob; Fu, Wei; Jin, Qi; Kerns,
     Jeffrey K.; Li, Huijie; Lin, Guoliang; Lin, Xichen; Neipp, Christopher E.
PA   Smithkline Beecham Corporation, USA
SO   PCT Int. Appl., 245pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2008118724        A1    20081002    WO 2008-US57583         20080320
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRAI US 2007-896558P      P     20070323
OS   MARPAT 149:425786
IT   860624-91-5P, 5-Bromo-1H-indole-7-carboxamide
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (preparation of indolecarboxamide derivs. for use as IKK2 inhibitors)
RN   860624-91-5  CAPLUS
CN   1H-Indole-7-carboxamide, 5-bromo-  (CA INDEX NAME)
```




```
RE.CNT  1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib hitstr 2

L21  ANSWER 2 OF 4  CAPLUS  COPYRIGHT 2009 ACS on STN
```

AN 2007:590757 CAPLUS
DN 147:30940
TI Preparation of indolecarboxamide derivatives as inhibitors of kinase activity
IN Kerns, Jeffrey K.; Busch-Petersen, Jakob; Li, Huijie; Boehm, Jeffrey Charles; Nie, Hong; Taggart, John J.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 86pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007062318	A2	20070531	WO 2006-US61018	20061117
	WO 2007062318	A3	20080117		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	EP 1948187	A2	20080730	EP 2006-846335	20061117
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	JP 2009516702	T	20090423	JP 2008-541484	20061117
	US 20080269291	A1	20081030	US 2008-93750	20080515
PRAI	US 2005-738393P	P	20051118		
	WO 2006-US61018	W	20061117		

OS MARPAT 147:30940
IT 860624-91-5P 860625-19-0P 860625-20-3P
860625-21-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of indolecarboxamide derivs. as inhibitors of kinase activity)
RN 860624-91-5 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo- (CA INDEX NAME)



RN 860625-19-0 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo-3-(4-piperidinyl)- (CA INDEX NAME)



RN 860625-20-3 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (CA INDEX NAME)



RN 860625-21-4 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo-3-[1-(ethylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



=> d bib hitstr 3-4

L21 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:33976 CAPLUS
DN 146:142511
TI Preparation of novel indolecarboxamides as IKK2 inhibitors
IN Deng, Jianghe; Kerns, Jeffrey K.; Jin, Qi; Lin, Guoliang; Lin, Xichen; Lindenmuth, Michael; Neipp, Christopher E.; Nie, Hong; Thomas, Sonia M.; Widdowson, Katherine L.
PA Smithkline Beecham Corporation, USA
SO PCT Int. Appl., 390pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007005534	A2	20070111	WO 2006-US25402	20060628
WO 2007005534	A3	20070426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006266028	A1	20070111	AU 2006-266028	20060628
CA 2613068	A1	20070111	CA 2006-2613068	20060628
EP 1896014	A2	20080312	EP 2006-785861	20060628
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2009500338	T	20090108	JP 2008-519569	20060628
IN 2007DN09298	A	20080627	IN 2007-DN9298	20071203
MX 2007016541	A	20080307	MX 2007-16541	20071218
KR 2008021077	A	20080306	KR 2007-730656	20071228
NO 2008000457	A	20080129	NO 2008-457	20080124
CN 101247804	A	20080820	CN 2006-80030448	20080221
PRAI US 2005-695256P	P	20050630		
WO 2006-US25402	W	20060628		

OS MARPAT 146:142511

IT 860626-56-8P 860626-65-9P 860626-67-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of novel indolecarboxamides as IKK2 inhibitors)

RN 860626-56-8 CAPLUS

CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[4-[(methylsulfonyl)amino]phenyl]- (CA INDEX NAME)



RN 860626-65-9 CAPLUS
CN 1H-Indole-7-carboxamide, 5-[4-(acetylamino)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 860626-67-1 CAPLUS
CN 1H-Indole-7-carboxamide, 5-[3-(acetylamino)phenyl]-3-[1-(ethylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



IT 860624-91-5P 860625-19-0P 860625-20-3P
860625-21-4P 860626-32-0P 860626-69-3P
860626-79-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel indolecarboxamides as IKK2 inhibitors)
RN 860624-91-5 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo- (CA INDEX NAME)



RN 860625-19-0 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo-3-(4-piperidinyl)- (CA INDEX NAME)



RN 860625-20-3 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)- (CA INDEX NAME)



RN 860625-21-4 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo-3-[1-(ethylsulfonyl)-4-piperidinyl]- (CA INDEX NAME)



RN 860626-32-0 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[4-(hydroxymethyl)phenyl]- (CA INDEX NAME)



RN 860626-69-3 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[3-(hydroxymethyl)phenyl]- (CA INDEX NAME)



RN 860626-79-5 CAPLUS
CN 1H-Indole-7-carboxamide, 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-(6-fluoro-3-pyridinyl)- (CA INDEX NAME)



L21 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2006:298630 CAPLUS
DN 144:350542
TI Indole derivatives as IKK2 inhibitors and their preparations, pharmaceutical compositions, and use for treatment of diseases associated with inappropriate IKK2 activity such as rheumatoid arthritis, asthma and chronic obstructive pulmonary disease
IN Kerns, Jeffrey K.; Lindenmuth, Michael; Lin, Xichen; Nie, Hong; Thomas, Sonia M.
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 220 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006034317	A2	20060330	WO 2005-US33752	20050921
	WO 2006034317	A3	20070419		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
	AU 2005286795	A1	20060330	AU 2005-286795	20050921
	CA 2581180	A1	20060330	CA 2005-2581180	20050921
	EP 1793826	A2	20070613	EP 2005-798511	20050921
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
	CN 101060842	A	20071024	CN 2005-80039763	20050921
	JP 2008513500	T	20080501	JP 2007-532632	20050921
	BR 2005015524	A	20080729	BR 2005-15524	20050921
	US 20070254873	A1	20071101	US 2007-575416	20070316
	MX 2007003283	A	20070518	MX 2007-3283	20070320

	IN 2007DN02158	A	20070803	IN 2007-DN2158	20070320
	NO 2007001988	A	20070418	NO 2007-1988	20070418
	KR 2007057969	A	20070607	KR 2007-709055	20070420
PRAI	US 2004-611761P	P	20040921		
	US 2005-695454P	P	20050630		
	WO 2005-US33752	W	20050921		

OS MARPAT 144:350542

IT 860624-91-5P 860625-06-5P 860625-19-0P
860625-23-6P 860625-25-8P 860625-44-1P
860626-15-9P 860626-16-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indole derivs. as IKK2 inhibitors and for treatment of diseases associated with inappropriate IKK2 activity such as rheumatoid arthritis, asthma and chronic obstructive pulmonary disease)

RN 860624-91-5 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo- (CA INDEX NAME)



RN 860625-06-5 CAPLUS
CN 1H-Indole-7-carboxamide, 5-phenyl- (CA INDEX NAME)



RN 860625-19-0 CAPLUS
CN 1H-Indole-7-carboxamide, 5-bromo-3-(4-piperidinyl)- (CA INDEX NAME)



RN 860625-23-6 CAPLUS
CN 1H-Indole-7-carboxamide, 3-(4-piperidinyl)-5-(2-thienyl)- (CA INDEX NAME)



RN 860625-25-8 CAPLUS
CN 1H-Indole-7-carboxamide, 3-(4-piperidinyl)-5-(3-thienyl)- (CA INDEX NAME)



RN 860625-44-1 CAPLUS
CN 1H-Indole-7-carboxamide, 5-(4-fluorophenyl)-3-(4-piperidinyl)- (CA INDEX NAME)



RN 860626-15-9 CAPLUS
CN 1H-Indole-7-carboxamide, 5-phenyl-3-[1,2,3,6-tetrahydro-1-(phenylmethyl)-4-pyridinyl]- (CA INDEX NAME)



RN 860626-16-0 CAPLUS
CN 1H-Indole-7-carboxamide, 5-phenyl-3-(4-piperidinyl)- (CA INDEX NAME)